Aspire Biopharma Holdings, Inc.
ASBP
$1.06
-$0.14-11.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -154.40% | 6.60% | 87.57% | -1,981.93% | -254.00% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 196.76% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.62% | -234.83% | -91.86% | -- | -- |
| Change in Net Operating Assets | 176.92% | 193.54% | -4.32% | -126.20% | 545.86% |
| Cash from Operations | 15.94% | 3.20% | 34.90% | -465.20% | 196.79% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | -100.00% | 719.29% | -200.00% |
| Total Debt Repaid | 99.53% | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 39.89% | -241.42% | -200.00% | -- | -- |
| Cash from Financing | -100.58% | -- | -100.00% | 728.30% | -200.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -154.21% | 252.77% | -184.91% | 10,510.08% | -316.13% |